HIV Reverse Transcriptase

Antiviral Agents
ATP-Dependent Removal of Nucleoside Reverse Transcriptase Inhibitors by Human Immunodeficiency Virus Type 1 Reverse Transcriptase
Lisa K. Naeger, Nicolas A. Margot, Michael D. Miller
Antiviral Agents
Pressure of Zidovudine Accelerates the Reversion of Lamivudine Resistance-Conferring M184V Mutation in the Reverse Transcriptase of Human Immunodeficiency Virus Type 1
Karidia Diallo, Maureen Oliveira, Daniela Moisi, Bluma Brenner, Mark A. Wainberg, Matthias Götte
Antiviral Agents
Effects of Specific Zidovudine Resistance Mutations and Substrate Structure on Nucleotide-Dependent Primer Unblocking by Human Immunodeficiency Virus Type 1 Reverse Transcriptase
Peter R. Meyer, Suzanne E. Matsuura, Adviye A. Tolun, Ingrid Pfeifer, Antero G. So, John W. Mellors, Walter A. Scott
Antiviral Agents
Human Immunodeficiency Virus (HIV) Type 1 Reverse Transcriptase Resistance Mutations in Hepatitis B Virus (HBV)-HIV-Coinfected Patients Treated for HBV Chronic Infection Once Daily with 10 Milligrams of Adefovir Dipivoxil Combined with Lamivudine
Constance Delaugerre, Anne-Geneviève Marcelin, Vincent Thibault, Gilles Peytavin, Tony Bombled, Marie-Valérie Bochet, Christine Katlama, Yves Benhamou, Vincent Calvez
Antiviral Agents
Emergence of Resistance to Protease Inhibitor Amprenavir in Human Immunodeficiency Virus Type 1-Infected Patients: Selection of Four Alternative Viral Protease Genotypes and Influence of Viral Susceptibility to Coadministered Reverse Transcriptase Nucleoside Inhibitors
Michael Maguire, Denise Shortino, Astrid Klein, Wendy Harris, Varsha Manohitharajah, Margaret Tisdale, Robert Elston, Jane Yeo, Sharon Randall, Fan Xu, Hayley Parker, Jackie May, Wendy Snowden
Antiviral Agents
Novel Use of a Guanosine Prodrug Approach To Convert 2',3'-Didehydro-2',3'-Dideoxyguanosine into a Viable Antiviral Agent
Adrian S. Ray, Zhenjun Yang, Chung K. Chu, Karen S. Anderson
Antiviral Agents
Variants Other than Aspartic Acid at Codon 69 of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase Gene Affect Susceptibility to Nucleoside Analogs
Mark A. Winters, Thomas C. Merigan
Antiviral Agents
Biochemical Mechanism of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Resistance to Stavudine
Johan Lennerstrand, David K. Stammers, Brendan A. Larder
Antiviral Agents
Potentiation of Inhibition of Wild-Type and Mutant Human Immunodeficiency Virus Type 1 Reverse Transcriptases by Combinations of Nonnucleoside Inhibitors and d- and l-(β)-Dideoxynucleoside Triphosphate Analogs
Giovanni Maga, Ulrich Hübscher, Massimo Pregnolato, Daniela Ubiali, Gilles Gosselin, Silvio Spadari
Antiviral Agents
Prevalence and Conditions of Selection of E44D/A and V118I Human Immunodeficiency Virus Type 1 Reverse Transcriptase Mutations in Clinical Practice
Constance Delaugerre, Mireille Mouroux, Anne Yvon-Groussin, Anne Simon, Francis Angleraud, Jean-Marie Huraux, Henri Agut, Christine Katlama, Vincent Calvez

Pages